Trial Success Rates by Phase & TA
PoS that survives IC scrutiny.
Phase-by-phase trial success rates conditioned on therapy area, modality and sponsor — built into a live PoS engine for portfolio and BD decisions.
"What PoS should we apply to this asset?"
Industry-average PoS misleads. TA × phase × modality × sponsor produces defensible numbers.
PoS is the highest-leverage number in clinical and R&D portfolio strategy. Defensible PoS is conditioned on therapy area, phase, modality and sponsor — never on a global average — and updated on every readout.
What we’re seeing in the data.
Onc P1→approval far below average
Solid-tumor IO and ADC programs trail industry mean.
Rare disease P3 PoS is unusually high
Smaller trials, biomarker selection, accelerated paths.
Sponsor track record matters measurably
Big pharma adds 5–15 PoS points vs first-time biotech.
How to think about it.
-
01
Anchor on TA × phase baseline
Published TA-specific PoS curves.
-
02
Adjust for modality
mAb, ADC, mRNA, ATMP, small molecule.
-
03
Adjust for sponsor
Track record + trial design quality.
-
04
Adjust for endpoint risk
Surrogate vs hard.
What separates a good answer from a defensible one.
Published rates over-state.
Positive ITT can mask weak sub-group data.
Some delays are CMC, not science.
Where the signal comes from.
Common questions.
Should we use industry-average PoS?
No — always TA × phase × modality × sponsor adjusted.
How often does PoS change?
Materially on every interim and primary readout.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist